Epidemiological characteristics and trends of hepatitis C in Hubei Province from 2004 to 2018
-
摘要:
目的 分析2004-2018年湖北省丙型肝炎(简称丙肝)的流行特征, 掌握丙肝发病状况, 为丙肝防控提供科学的意见和建议。 方法 研究收集传染病报告信息管理系统中丙肝报告病例的数据, 对其进行描述性分析并使用时间序列模型进行分析预测。 结果 丙肝发病率呈持续增加趋势, 从2004年的1.82/105增加到2018年的18.51/105, 年平均增长率为18.01%。各年龄段丙肝发病率随年份的增加整体呈上升趋势, 在同一年份, 发病率随年龄段的增加而出现先上升后下降的趋势, 在60~70岁年龄段达到顶峰。丙肝的新发患者中排行前三的职业依次为农民、家务及待业、离退休人员, 其总占比超过80%。通过时间序列模型预测, 如果不采取有效控制措施, 5年后丙肝发生率可超过24.88/105。 结论 丙肝发病率持续升高, 发病有较明显的人群、空间分布特点, 需要密切关注并且针对性地采取有效措施, 减少疾病的发生和感染。 Abstract:Objective This study aims to know the incidence of hepatitis C and provide scientific opinions and suggestions for prevention and control of hepatitis C through analyzing the characteristics of hepatitis C in Hubei Province from 2004 to 2018. Methods Data of hepatitis C reported cases in the infectious disease report information management system were collected, analyzed and predicted by time series model. Results The incidence of hepatitis C continued to increase, from 1.82/105 in 2004 to 18.51/105 in 2018, with an average annual growth rate of 18.01%. The incidence of hepatitis C in all age groups increased from 2004 to 2018. In the same year, the incidence rate increased initially and then decreased with the elder age group. The peak was in 60-70 age group. Among the new diagnosed patients with hepatitis C, the top three occupations were farmers, housework and unemployed, retired people, accounting for more than 80% of the total. According to the prediction of time series model, the incidence of hepatitis C could exceed 24.88/105 after 5 years if no effective control measures were taken. Conclusions The incidence of hepatitis C is still rising, and it has significant population and spatial distribution pattern. It is necessary to pay attention and take effective measures to reduce the incidence of new infections and diseases onset. -
Key words:
- Hepatitis C /
- Epidemiologic characteristic /
- Prediction
-
表 1 2004-2018年丙肝发病和死亡情况
Table 1. The incidence and the mortality of hepatitis C from 2004 to 2018
年份 发病数(例) 发病率(/105) 死亡数(例) 死亡率(/105) 2004 1 095 1.823 6 0.001 2005 1 518 2.667 4 0.007 2006 2 249 3.939 10 0.018 2007 3 259 5.725 5 0.009 2008 3 866 6.784 7 0.012 2009 4 798 8.401 4 0.007 2010 5 009 8.757 3 0.005 2011 6 092 10.643 3 0.005 2012 6 350 11.028 10 0.017 2013 7 350 12.719 9 0.016 2014 7 896 13.616 5 0.009 2015 8 736 15.021 0 < 0.001 2016 9 453 16.958 2 0.003 2017 10 419 17.704 3 0.005 2018 10 926 18.512 4 0.007 -
[1] 付睿, 陆长春, 刘慧.利巴韦林配伍PEG-IFNα-2a治疗对老年慢性丙肝患者血清可溶性Fas、FasL水平及T细胞亚群的影响[J].中国老年学杂志, 2019, 39(11): 2664-2667. DOI: 10.3969/j.issn.1005-9202.2019.11.032.Fu R, Lu CC, Liu H. Effects of ribavirin combined with PEG-IFNα-2a on serum soluble Fas, FasL levels and T cell subsets in elderly patients with chronic hepatitis C[J]. Chin J Geriatr, 2019, 39(11): 2664-2667. DOI: 10.3969/j.issn.1005-9202.2019.11.032. [2] 陈若蝉, 刘振国, 范学工. DAA与HCC--丙肝治疗新时代的挑战[J].中国感染控制杂志, 2018, 17(5): 369-372. DOI: 10.3969/j.issn.1671-9638.2018.05.001.Chen RC, Liu ZG, Fan XG. DAA and HCC-Challeng einthene wear of hepatitis Ctreatment[J]. Chin J Infect Control, 2018, 17(5): 369-372. DOI: 10.3969/j.issn.1671-9638.2018.05.001. [3] 常峰, 段承阿鑫, 金琇泽, 等.我国丙型肝炎治疗现状与相关医疗保障补偿机制分析及建议[J].中国药房, 2018, 29(2): 151-155. DOI: 10.6039/j.issn.1001-0408.2018.02.02.Chang F, Duan CAX, Jin YZ, et al. Analysis and suggestions on the situation ofhepatitis C treatment and related medical insurancecompensation mechanism in China[J]. China Pharmacy, 2018, 29(2): 151-155. DOI: 10.6039/j.issn.1001-0408.2018.02.02. [4] Das D, Pandya M. Recent advancement of direct-acting antiviral agents(DAAs)in hepatitis C therapy[J]. Mini Rev Med Chem, 2018, 18(7): 584-596. DOI: 10.2174/1389557517666170913111930. [5] Pradat P, Virlogeux V, Trépo E. Epidemiology and elimination of HCV-related liver disease[J]. Viruses, 2018, 10(10): 545. DOI: 10.3390/v10100545. [6] Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57(4): 1333-1342. DOI: 10.1002/hep.26141. [7] Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 161-176. DOI: 10.1016/S2468-1253(16)30181-9. [8] 中华人民共和国国家卫生和计划生育委员会. WS 213-2018丙型肝炎诊断[J].临床肝胆病杂志, 2018, 34(8): 1619-1621. DOI: 10.3969/j.issn.1001-5256.2018.08.006.National Health and Family Planning Commission of the People's Republic of China. WS 213-2018 diagnosis for hepatitis C[J]. J Clin Hepatol, 2018, 34(8): 1619-1621. DOI: 10.3969/j.issn.1001-5256.2018.08.006. [9] 董旻晔, 肖煜吟, 贾芷莹, 等.基于时间序列模型的全国监测地区婴儿死亡率预测分析[J].中国妇幼保健, 2019, 34(14): 3156-3159. DOI: 10.7620/zgfybj.j.issn.1001-4411.2019.14.04.Dong MY, Xiao YY, Jia ZY, et al. Prediction of infant mortality in national surveillance areas based on time series model[J]. Maternal and Child Health Care of China, 2019, 34(14): 3156-3159. DOI: 10.7620/zgfybj.j.issn.1001-4411.2019.14.04. [10] 宇方, 陈婷婷, 唐倩, 等.利用ARIMA模型对医院感染现患率进行预测[J].中华医院感染学杂志, 2019, 29(8): 1246-1250. DOI: 10.11816/cn.ni.2019-184032.Yu F, Chen TT, Tang Q, et al. Prediction of prevalence rate of nosocomial infection by using ARIMA model[J]. Chin J Nosocomiol, 2019, 29(8): 1246-1250. DOI: 10.11816/cn.ni.2019-184032. [11] 刘刚, 唐宋, 孙文杰.时间序列分析法在香港结核病预测中的应用[J].中国卫生统计, 2012, 29(2): 226-228. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwstj201202021Liu G, Tang S, Sun WJ. Application of time series analysis in tuberculosis prediction in Hong Kong[J]. Chin J Health Stati, 2012, 29(2): 226-228. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgwstj201202021 [12] Ansaldi F. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy[J]. World J Gastroenterol, 2014, 20(29): 9633. DOI: 10.3748/wjg.v20.i29.9633. [13] 裴晓迪, 刘伦皓, 刘莉, 等. 2014年四川省丙型病毒性肝炎病例报告数据质量核查结果分析[J].职业卫生与病伤, 2018, 33(6): 348-351. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zywsybs201806007Pei XD, Liu LH, Liu L, et al. The results of quality check of case reporting data ofhepatitis C in Sichuan in 2014[J]. Occupational Health and Damage, 2018, 33(6): 348-351. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zywsybs201806007 [14] 赵亚栋, 屠爱霞, 王晓蕊, 等.甘肃省2004-2018年丙型肝炎流行特征[J].中华疾病控制杂志, 2019, 23(8): 922-926. DOI: 10.16462/j.cnki.zhjbkz.2019.08.008.Zhao YD, Tu AX, Wang XR, et al. Epidemiologic characteristics of hepatitis C in Gansu Province from 2004 to 2018[J]. Chin J Dis Control Prev, 2019, 23(8): 922-926. DOI: 10.16462/j.cnki.zhjbkz.2019.08.008. [15] 陈锁玉, 李世福, 蒋丹兰, 等. 2005-2017年玉溪市丙型病毒性肝炎流行特征与趋势分析[J].现代预防医学, 2019, 46(17): 3217-3220. http://www.cnki.com.cn/Article/CJFDTotal-XDYF201917032.htmChen SY, Li SF, Jiang DL, et al. Epidemiological trends and characteristics of hepatitis C in Yuxi, 2005-2017[J]. Modern Prevent Med, 2019, 46(17): 3217-3220. http://www.cnki.com.cn/Article/CJFDTotal-XDYF201917032.htm [16] 赵庆龙, 吕波, 李美娜, 等. 1997-2012年吉林省丙型病毒性肝炎流行病学特征分析[J].中华疾病控制杂志, 2014, 18(7): 594-596. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jbkzzz201407003Zhao QL, Lv B, Li MN, et al. Epidemic situation of hepatitis C in Jilin Province, 1997-2012[J]. Chin J Dis Control Prev, 2014, 18(7): 594-596. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jbkzzz201407003